eMethods 1: Study design and subject selection. eMethods 2: Determinations of clinical chemistry parameters and drug plasma concentrations. eMethods 3: Exploratory analysis. eMethods 4: Confirmatory Analysis. eResults 1: Metabolic parameters. eTable 1: Baseline demographics stratified by gender. eTable 2: Metabolic parameters and syndrome at baseline, 3 months and one year.
eMethods 1: Study design and subject selection.
Patients with missing weight at baseline or at one month were excluded from analysis (eFigure 1). If two or more studied drugs (clozapine, olanzapine, risperidone, quetiapine, aripiprazole, amisulpride, lithium, valproate and/or mirtazapine) were prescribed concomitantly, the latest introduced compound was considered as the main treatment and the other drugs were pooled with co-medication possibly inducing weight gain (eTable 10). Medications could be changed by the treating physician according to the response to treatment and side-effects with no influence of the inclusion of patients in the study (non-interventional study).Weight was measured in the morning in fasting conditions by using professional medical scales. No retrospective or self-estimated patient data was used. Appetite assessment was based on a five item scale (self evaluation): low, moderate, medium, high and very high appetite. Physical activity, which was defined as walking, climbing stairs or specific sport activity, was based on daily physical activity duration (self evaluation): <30 min, 30-60 min, >60 min. For statistical tests on long term weight gain, appetite increase was defined as an elevation of appetite between baseline and the first month of treatment (eg. low to moderate, moderate to high). In addition, physical activity was defined by the daily activity duration at one month treatment (less vs equal or more than 30 minutes).
eMethods 2: Determinations of clinical chemistry parameters and drug plasma concentrations.
Metabolic syndrome (MetS) prevalence was assessed according to the Adult Treatment Panel III (ATP III) 3 , the adapted definition (ATP III-A) 4 and the International Diabetes Federation (IDF) 5 which has different cut-offs for waist circumference (WC) depending on the ethnicities (e.g. for the 95% of our patients who are Caucasian, Sub-Saharan Africans, Eastern Mediterranean and Middle East populations, WC of 90 cm for men and 80 cm for women are used for the definition of metabolic syndrome. This same cut-off was used for the 5% other patients who were Asians (n=2) or of unknown ethnic group (n=17)). Blood samples were drawn in the morning in fasting conditions (blood samples drawn after 10H00 AM were excluded from analysis) to measure clinical chemistry parameters and drug plasma concentrations. Plasma drug concentrations were quantified at one, three and 12 months in trough conditions (in the morning before the next drug intake). Liquid chromatography/mass spectrometry methods were used for measuring aripiprazole, clozapine, or olanzapine plasma levels as previously described 6 , and also for risperidone, OH-risperidone, quetiapine or amisulpride (Eap et al., unpublished data, available on request). Mirtazapine was measured by gas-chromatography-nitrogen detector (Eap et al., unpublished data, available on request), valproate by fluorescence polarization immunoassay (Cobas integra 400 plus Roche®, Roche Diagnostic, Rotkreuz, Switzerland) and lithium by ion selective electrode (EasyLyte Na/K/Cl/Li, Medica®, Chatel St-Denis, Switzerland). All methods are used on a routine basis in our accredited laboratory (ISO 15189 and 17025), with external quality controls (LGC Standards Proficiency Testing (Teddington, United Kingdom); Arvecon (Walldorf, Germany; Quality Control Centre Switzerland (Chêne-Bourg, Switzerland)). Patients were considered compliant when drug plasma concentrations were higher than 10 % of the lower value of the recommended therapeutic range 7 . For this purpose, for all substances except risperidone, the concentration of the prescribed drug was used, while for risperidone, the sum of risperidone and of its metabolite 9-OH risperidone was used. Drug plasma concentration at month one and three, and at month one and 12 were evaluated for follow ups shorter or equal to 12 months, respectively. Reports of non-compliance as observed by the medical or nursing staff were also taken into account. Patients who were considered non-compliant at any of the time periods of observations were excluded from analysis.
Patients' blood pressures were measured once after five minutes rest in a sitting position.
eMethods 3: Exploratory analysis.
Marginal analyses were done using Wilcoxon rank-sum (W+) and Kruskal-Wallis tests (KW) for comparing continuous traits. Fisher's exact tests (FET) were used to compare categorical variables and McNemar tests (MN) were used to compare the prevalence of outrange metabolic parameters between baseline, three and 12 months. Thresholds for early WG were examined by 1% increments (ranging from 2% to 8%) to find the best predictors for long term WG as defined by a minimal WG of 10%, 15% or 20% at 3 and 12 months of treatment. These analyses allowed to assess the best relation between SN and SP to find an acceptable threshold for short and long term WG. To explore the adequacy of linear evolution of BMI along time, a Generalized Additive Mixed Model (GAMM) was also fitted to the same data. The response variable in this model corresponded to the ratio of the weight at each time point divided by the weight at baseline, which represents the weight gain at that time point. Observations made at two, three, six, nine and 12 months (analyzed as a continuous variable) were used to fit the model, while observations made at baseline and at the first month were used to construct the grouping variable. The effect of time on weight gain was not considered as linear but was better represented by a smooth semi-parametric curve (with cubic regression spline basis). GAMMs were fitted separately for each sub-group to give the possibility of capturing the weight-gain trend without restraint at each sub-group (otherwise, a parallel trend in time would have been imposed on all sub-groups). These models were not adjusted for multiple comparisons, covariates or cofactors as they were used only to explore the data and the adequacy of the final model.
eMethods 4: Confirmatory Analysis.
The "nlme" package of R 8 was used to fit a linear mixed effect model adjusted for age (at baseline), gender, BMI (at baseline), psychotropic drugs, presence of co-medication possibly inducing weight gain, triglycerides, glucose and HDL concentrations. The fitted linear mixed effect model 9 had a random effect at the subject level. To be more robust in inferences, a bootstrap analysis 10 was used to evaluate the uncertainty of estimated parameters (evaluated uncertainties are more conservative, but more reliable if there are violations from model assumptions, as normality assumption for residuals). Results were based on 10000 bootstrap replicates at the subject level (subjects were considered to be independently recruited) and increasing the number of bootstraps did not influence substantially the uncertainty of estimated parameters.
eResults 1: Metabolic parameters.
Abdominal obesity (M≥94cm, F≥80cm) was observed in 54% of patients at baseline, and increased from 49% to 62% after one year (p=0.02, table 2) in patients with one year follow-up. This prevalence increased significantly with age (from 30% to 66% at baseline, p=0.001 and from 45% to 76% at one year, p=0.004) (eTable 3).Hypo HDL-cholesterolemia (M≤1.03mmol/l; F≤1.29mmol/l)) was observed in 31% of patients at baseline with no evolution during treatment. Prevalence at baseline was higher in women except in elderly patients (young, p=0.02; young adults, p=0.03: adults, p=0.01). Baseline hypertriglyceridemia (≥1.7mmol/l or presence of lipid lowering drug) was observed in 28% of the patients at baseline. In patients with baseline and one year data, hypertriglyceridemia increased from 21% to 40% after one year (p=0.006). Hypertriglyceridemia increased along the four age categories from 8% to 36% at baseline (p=0.01) (eTable 3). Hyperglycemia or diabetes (≥5.6mmol/l or antidiabetic medication) was observed in 25% of patients at baseline. In patients with baseline and one year data, hyperglycemia increased from 16% to 38% (p=0.002). No gender differences were observed at baseline and after one year, however hyperglycemia was significantly increased with increasing age (p=0.003). No gender differences in the prevalence of hypertension (130/85mmHg or antihypertensive medication) were observed, with an unchanged prevalence during treatment. However, as expected, hypertension was found to increase significantly with increasing age both at baseline and after one year (p=0.001). Prevalence of metabolic syndrome (MetS, IDF definition) was 22% at baseline. In patients with baseline and one year data, a trend for an increased prevalence during treatment was observed (from 9% to 23%, p=0.07). In agreement with other parameters, MetS increases with increasing age (6% to 44%, p=0.001) at baseline, however no significant age related increase was observed after one year. The left column indicates the weight change after one month and the second left column indicates the weight change after 3 months (upper panel) and 12 months (lower panel). In Bold, the retained prediction based on the highest AUC for 3 and 12 months. Abbreviations: PPV = positive predictive values, NPV = negative predictive values, AUC = area under the curve. The left column indicates the weight change after one month and the second left column indicates the weight change after 3 months (upper panel) and 12 months (lower panel). In Bold, the retained prediction based on the highest AUC for 3 and 12 months. Abbreviations: PPV = positive predictive values, NPV = negative predictive values, AUC = area under the curve. 5  36  58  54  53  54   10  15  83  53  51  52   15  5  94  55  51  53   12 Months   5  52  44  53  51  52   10  21  67  62  53  57   15  12  78  67  52  59 Upper panel indicates the weight increase at 3 months and the lower panel a weight increase at 12 months. Abbreviations: PPV = positive predictive values, NPV = negative predictive values, AUC = area under the curve. eTable 9: Receiver operating parameters for an appetite increase between baseline and one month predicting a weight gain at 3 and 12 months. Upper panel indicates the weight increase at 3 months and the lower panel a weight increase at 12 months. Abbreviations: PPV = positive predictive values, NPV = negative predictive values, AUC = area under the curve. 
